Correvio Pharma (NASDAQ: CORV) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Correvio Pharma to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.
This table compares Correvio Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Correvio Pharma Competitors||-2,655.97%||-68.43%||-24.43%|
This table compares Correvio Pharma and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Correvio Pharma||$24.00 million||-$29.81 million||-3.76|
|Correvio Pharma Competitors||$1.96 billion||$127.27 million||-7.88|
Correvio Pharma’s peers have higher revenue and earnings than Correvio Pharma. Correvio Pharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
45.4% of Correvio Pharma shares are held by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Correvio Pharma and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Correvio Pharma Competitors||3685||10817||24662||806||2.57|
Correvio Pharma currently has a consensus price target of $11.00, suggesting a potential upside of 225.44%. As a group, “Pharmaceutical preparations” companies have a potential upside of 64.25%. Given Correvio Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Correvio Pharma is more favorable than its peers.
Volatility & Risk
Correvio Pharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. Comparatively, Correvio Pharma’s peers have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Correvio Pharma peers beat Correvio Pharma on 8 of the 13 factors compared.
About Correvio Pharma
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. Its portfolio of marketed brands also comprise Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome; and Esmocard and Esmocard Lyo (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in various cardiovascular indications. The company's product candidates that are in development include Trevyent, a drug device combination that is designed to deliver treprostinil for pulmonary arterial hypertension. Correvio Pharma Corp. is headquartered in Vancouver, Canada.
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.